Loading...
Market
How many countries will approve Sasanlimab with BCG by end of 2025?
2
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Global regulatory body announcements and approvals
Story
Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer
Jan 10, 2025, 11:52 AM
Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.
View original story
Similar markets
1-4 countries • 25%
15 or more countries • 25%
10-14 countries • 25%
5-9 countries • 25%
30 to 60 countries • 25%
More than 90 countries • 25%
60 to 90 countries • 25%
Fewer than 30 countries • 25%
No countries • 25%
More than 10 countries • 25%
6 to 10 countries • 25%
1 to 5 countries • 25%
81 to 120 • 25%
More than 120 • 25%
50 to 80 • 25%
Less than 50 • 25%
30 to 60 countries • 25%
More than 90 countries • 25%
Fewer than 30 countries • 25%
60 to 90 countries • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
Approved in UK and EU • 25%
Approved in UK only • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
Less than 5 • 25%
1 to 5 • 25%
More than 10 • 25%
6 to 10 • 25%
0 • 25%
Two • 25%
One • 25%
Three or more • 25%
None • 25%
Approved in the EU • 25%
Approved in the USA • 25%
Not approved in any major market • 25%
Approved in other major markets • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
